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OBJECTIVE: To evaluate the effect of tumor capsule rupture
on disease prognosis in stage I epithelial ovarian cancer.
METHODS: All patients with International Federation of
Gynecology and Obstetrics stage I epithelial ovarian
cancer operated on at the Mayo Clinic and The Ohio
State University between January 1991 and December
2007 were identified. Relevant tumor characteristics,
procedures performed, adjuvant therapies, and fol-
low-up were recorded and analyzed. Inclusion criteria
included comprehensive staging. Cox proportional
hazards, Kaplan-Meier estimation, log rank test, and 2
test were used for statistical analyses.
RESULTS: There were 161 cases that met inclusion crite-
ria. Seventy-four (46%) patients had intact capsules with-
out positive cytology or surface involvement; 61 (38%)
had capsule rupture; 33 (20%) had positive cytology; and
22 (14%) had surface involvement. Overall, 22 of 161
(14%) patients recurred and 12 of 161 (7%) patients died
of their disease. In univariable analysis, both intraopera-
tive capsule rupture and positive cytologic washings
portended worse disease-free survival (hazard ratio [HR]
3.6, 95% confidence interval [CI] 1.5–8.9; P.004 and HR
5.2, 95% CI 2.1–12.3; P<.001, respectively) and disease-
specific survival (HR 4.1, 95% CI 1.3–15.4; P.018 and HR
5.9, 95% CI 1.8–19.3; P.005, respectively). In multivari-
able analysis, capsule rupture (HR 4.2, 95% CI 1.8–10.9;
P.001) and positive cytologic washings (HR 6.4, 95% CI
2.5–16.0; P<.001) remained independent predictors of
worse disease-free survival. Disease-free survival and
disease-specific survival were shortest for stage IC cases
with positive cytology, surface involvement, or both, that
also had intraoperative rupture.
CONCLUSION: In stage I epithelial ovarian cancer, in-
traoperative capsule rupture portends a higher risk of
disease recurrence and death from disease. Careful in-
traoperative removal of ovarian masses is important, and
recognizing the higher-risk nature of such cases is imper-
ative.
(Obstet Gynecol 2009;113:11–7)
LEVEL OF EVIDENCE: III
Epithelial ovarian cancer is the second most com-mon gynecologic malignancy in the United States.
In 2008, an estimated 21,650 new cases will be
diagnosed and an estimated 15,520 women will die of
the disease, making it the most deadly gynecologic
malignancy.1 Although more than 60% of cases are
diagnosed in advanced stages (stages III and IV),
stage I represents one quarter of all new epithelial
ovarian cancer diagnoses, and the overall 5-year
survival is reported to be between 70% and 89%.2–4
Epithelial ovarian cancer staging is surgical and is
based on the 1988 International Federation of Gyne-
cology and Obstetrics (FIGO) staging criteria.5 Stage
IA encompasses all unilateral, unruptured ovarian
cancers without surface involvement. Stage IB epithe-
lial ovarian cancers are bilateral, unruptured, and
without surface involvement. Epithelial ovarian can-
cers confined to the ovary are assigned to stage IC if
there is evidence of capsule surface involvement or
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positive cytology in peritoneal washings obtained at
time of exploration. In addition, if the capsule of a
stage IA or IB cancer is ruptured either preoperatively
or intraoperatively, the patient is upstaged to stage IC.
When patients are managed only with surgery, the
overall 5-year survival for stage IA approaches 94%
and stage IB 92%, whereas 5-year survival for stage IC
is 84% in some series.2 For stage I epithelial ovarian
cancer overall, the 5-year recurrence-free survival
after appropriate staging and adjuvant chemotherapy
approaches 85%.6
The standard of care today for management of
epithelial ovarian cancer includes surgical staging and
tumor cytoreduction when indicated, followed by
adjuvant platinum-based chemotherapy.7 This ap-
proach has yielded improved disease-free survival
and overall survival.8–11 Factors that delineate which
early-stage patients are at highest risk for recurrence
are used to determine whether to administer adjuvant
chemotherapy. Important prognostic factors include
grade, histologic subtype, and substage.12 Optimal
adjuvant treatment of high-risk early stage epithelial
ovarian cancer continues to be debated (Markman M.
Re: “Randomized phase III trial of three compared with
six cycles of adjuvant carboplatin and paclitaxel in early
stage epithelial ovarian carcinoma: a Gynecologic On-
cology Group study” [letter]. Gynecol Oncol 2007;105:
279–80).3 However, it is generally agreed that after
comprehensive staging, well-differentiated or moder-
ately differentiated stage IA cancers do not benefit from
adjuvant chemotherapy, because their overall prognosis
is excellent without adjuvant treatment.9,12,13,14 In addi-
tion, per the National Comprehensive Center Network
guidelines, both comprehensively staged grade 1 and 2,
stage IA and IB epithelial ovarian cancer can be ob-
served.15 For all other categories of stage I disease,
adjuvant treatment is recommended.
One area of conflict is the prognostic significance
of capsule rupture during surgery in a case that would
otherwise be assigned to stage IA or IB. Several
studies have suggested that intraoperative rupture of
an intact capsule does not affect prognosis,2,16,17
whereas others indicate intraoperative rupture is an
independent predictor of decreased disease-free sur-
vival18–21 and worse overall survival.19 Unfortunately,
most of these studies are limited by inclusion of
nonstaged or incompletely staged cases, lack of con-
sistent adjuvant treatments, and lack of subset analy-
ses of categories within stage IC tumors. These limi-
tations make interpretation of the existing literature
fraught with errors. We designed this retrospective
study to investigate the effect of intraoperative capsule
rupture on disease-free survival and disease-specific
survival in patients with stage I epithelial ovarian
cancer who were completely staged and all treated
during the platinum chemotherapy era according to
similar standards.
MATERIALS AND METHODS
After institutional review board approval at both
institutions, all cases of stage I epithelial ovarian
cancer were identified that had their initial diagnoses
and staging procedures either at The Mayo Clinic or
at The Ohio State University College of Medicine
between January 1991 and December 2007. Medical
records were reviewed and data abstracted, including
demographics, surgical stage, tumor grade, operative
staging procedures, intraoperative findings, adjuvant
therapies, and follow-up, including recurrence and
death events. Inclusion criteria included complete
records, comprehensive staging, staging operation
performed at either the Mayo Clinic or The Ohio
State University, and patient consent for review of
their medical records. Comprehensive surgical
staging was defined as exploratory laparotomy,
collection of cytologic washings, hysterectomy (if
uterus present), bilateral salpingo-oophorectomy,
bilateral pelvic and paraaortic lymphadenectomy,
omentectomy, and peritoneal biopsies. Patients
were excluded from the analysis if they did not
undergo one or more of the staging procedures.
Patients were excluded if they were referred for
staging after the diagnosis was made elsewhere or
distant in time from the diagnostic operative pro-
cedure or if they had preoperative drainage or cyst
aspiration. All cases were either independently
reviewed by a single gynecologic pathologist (Mayo
Clinic) or re-reviewed by a gynecologic pathologist
at tumor board as part of clinical decision making
(The Ohio State University College of Medicine).
For the purpose of identifying and separating the
various indications for assignment to stage IC, we
defined substages of stage IC as follows: ICr—patients
who had intraoperative capsule rupture as their only
stage IC qualification (eg, no surface involvement and
negative cytology); ICs/w, no rupture—patients with
surface excrescences and/or positive cytologic wash-
ings whose tumors were removed intact; ICs/w, with
rupture—patients with surface excrescences and/or
positive cytologic washings whose tumors also rup-
tured intraoperatively.
The primary outcomes chosen were disease-free
survival and disease-specific survival. Disease-specific
survival was chosen instead of overall survival because
many patients with early stage disease who are rendered
disease free will die from other causes without recur-
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rence. Cox proportional hazards, Kaplan-Meier estima-
tion, log rank test, and 2 test were used for statistical
analyses. Stepwise multivariable analysis was performed
to determine factors significantly affecting disease-free
survival. Due to the small number of patients who died
from disease, multivariable analysis of factors affecting
disease-specific survival was not performed. The JMP
7.0 (SAS Institute Inc., Cary, NC) statistical program
was used for all analyses.
RESULTS
During the study interval, there were 161 patients
diagnosed with surgical stage I epithelial ovarian
cancer who underwent comprehensive surgical stag-
ing. All patients underwent immediate comprehen-
sive surgical staging after intraoperative frozen section
determination of cancer.
Substaging was as follows: 65 (40%) FIGO stage
IA, 9 (6%) IB, and 87 (54%) IC. Thirty-eight (44%) of
the stage IC cases would have been considered stage
IA or IB if the tumor capsule had remained intact.
Overall, for the 87 cases of IC disease, the reasons for
upstaging were as follows: 38 (44%) secondary to
intraoperative capsule rupture only (ICr); 26 (30%)
due to ovarian surface involvement with tumor
and/or positive cytology from washings and no intra-
operative rupture of the capsule (ICs/w, no rupture);
and 23 (26%) due to ovarian surface involvement with
tumor and/or positive cytology from washings in
addition to intraoperative rupture of the capsule
(ICs/w, with rupture) (Table 1).
Overall, 22 patients (14%) developed recurrent
disease, and 12 patients (7%) died of disease. The
median follow-up among the 139 patients alive at the
time of last follow-up was 44.7 months (range 0.2–185
months, mean 54.1 months). Meanstandard devia-
tion pelvic and paraaortic lymph node counts were
26.813.8 and 11.77.2, respectively.
In univariable analysis, capsule rupture por-
tended a lower disease-free survival (hazard ratio
[HR] 3.6, 95% confidence interval [CI] 1.5–8.9;
P.004) (Table 2) and a lower disease-specific sur-
vival (HR 4.1, 95% CI 1.3–15.4; P.018) (Table 3).
When controlling for positive cytology, intraoperative
capsule rupture remained a predictor of poorer dis-
ease-free survival (HR 4.2, 95% CI 1.8–10.9; P.001).
There was similar disease-free survival (P.84,
log rank) and disease-specific survival (P.97, log
rank) among patients who were assigned to stage IC
due to a single factor alone (eg, only positive cytology
or surface involvement or capsule rupture). Among
all stage IC cases, the shortest disease-free survival
and disease-specific survival were observed in pa-
tients who had a combination of positive cytology
and/or surface involvement along with intraoperative
capsule rupture (ICs/w, with rupture). Patients classi-
fied as ICs/w, with rupture had significantly worse
disease-free survival (HR 3.3, 95% CI 1.1–12.1;
Table 1. Stage I Epithelial Ovarian Cancer Patient
Characteristics, Substage, Tumor
Characteristics, and Adjuvant Therapy
Characteristics
Patients
(n161)
Age (y)
Mean (range) 56 (23–83)
Median 58
Substage
IA 65 (40)
IB 9 (6)
IC 87 (54)
Intraoperative rupture only
(ICr)*
38 (44)
Surface involvement and/or
positive cytology without
capsule rupture (ICs/w, no
rupture)†
26 (30)
Surface involvement and/or
positive cytology and
capsule rupture (ICs/w, with
rupture)‡
23 (26)
Individual stage IC factors (among
all stage IC patients)
Intraoperative capsule rupture
occurred
61 (38)
Positive cytology 33 (20)
Surface involvement present 22 (14)
Grade
1 34 (21)
2 45 (28)
3 82 (51)
Tumor histology
Serous 29 (18)
Clear cell 35 (22)
Mucinous 27 (17)
Endometrioid 59 (37)
Other§ 11 (6)
Tumor mobility
Mobile 74 (46)
Fixed 77 (48)
Not recorded 10 (6)
Platinum-based chemotherapy
received
Yes 106 (66)
No 55 (34)
Data are n (%) except where otherwise specified.
* Based on operative note; intraoperative rupture as only indication
for stage IC.
† Surface involvement based on pathology findings and/or positive
cytology from washings, no capsule rupture.
‡ Surface involvement based on pathology findings and/or positive
cytology from washings, and capsule rupture.
§ Mixed, transitional cell, and seroanaplastic.
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P.041) compared with ICs/w, no rupture patients.
Disease-specific survival was not significantly differ-
ent between these two cohorts; however, there were
only three (of 26) ICs/w, no rupture patients and five
(of 23) ICs/w, with rupture patients who died from
disease, thus limiting power. Patients assigned to IC
solely due to rupture (ICr) had outcomes similar to
those assigned to IC due to surface involvement
and/or positive cytology (ICs/w, no rupture) (Fig. 1).
There were 38 (44%) stage IC patients who were
upstaged to IC from IA/B disease based solely on
intraoperative capsule rupture (ICr). These patients
all had negative cytologic washings before tumor
manipulation as well as no ovarian surface excres-
cences on final pathology. There were five recur-
rences (13.2%) and three deaths from disease (7.9%)
among the 38 ICr patients; there were four recur-
rences (5.4%) and only one death from disease (1.4%)
among the 74 IA/B patients. In time-to-event analy-
ses, differences in disease-free survival (HR 2.7, 95%
CI 0.7–10.9; P.14) (Fig. 2) and disease-specific sur-
vival (HR 5.3, 95% CI 0.7–107.8; P.12) between
stages IA/B and ICr were observed but they were not
statistically significant. This also likely reflects the
limited power due to the small number of events.
Overall, disease-free survival was shorter (HR 5.0,
95% CI 1.9–17.3; P.001), and disease-specific
survival was shorter (HR 10.6, 95% CI 2.0–193.8;
P.002), for combined stage IC cases compared with
stage IA/B cases.
Clear descriptions of the ovarian tumors’ intraop-
erative mobility were available for 151 of 161 (94%)
cases such that we could accurately classify them as
either fixed or mobile. Nearly an equal percentage of
tumors were described as mobile (46%) as were
described as fixed (48%) in the operative notes (Table
1). There was no correlation between tumor mobility
and surface involvement of tumor (P.36, 2) or
positive cytology (P.47, 2). There was a higher rate
of capsule rupture when tumors were described by
Table 3. Univariable Analysis of Factors Important
in Disease-Specific Survival
Variable HR (95% CI) P
Capsule rupture (yes) 4.1 (1.3–15.4) .018
Cytology (positive) 5.9 (1.8–19.3) .005
Surface involvement (yes) 2.4 (0.5–8.4) .23
Grade (high) 5.5 (1.4–36.1) .011
Tumor mobility (fixed) 1.2 (0.4–4.2) .77
Received platinum-based
chemotherapy (yes)
4.0 (0.8–74.3) .11
Stage (1C vs 1A/B) 10.6 (2.0–193.8) .002
HR, hazard ratio; CI, confidence interval.
Table 2. Univariable Analysis of Factors Important
in Disease-Free Survival
Variable HR (95% CI) P
Capsule rupture (yes) 3.6 (1.5–8.9) .004
Cytology (positive) 5.2 (2.1–12.3) .001
Surface involvement (yes) 2.6 (0.9–6.4) .064
Grade (high) 2.3 (1.0–5.9) .064
Tumor mobility (fixed) 1.6 (0.7–4.4) .29
Received platinum-based
chemotherapy (yes)
1.7 (0.6–6.0) .31
Stage (1C vs 1A/B) 5.0 (1.9–17.3) .001
HR, hazard ratio; CI, confidence interval.
Fig. 1. Subclassification of stage IC and effect on A.
disease-free survival (P.008, log rank test) and B. disease-
specific survival (P.042, log rank test). ICr, stage IC,
secondary to capsule rupture only. ICs/w, no rupture—
patients with surface excrescences and/or positive cytologic
washings whose tumors were removed intact; ICs/w, with
rupture—patients with surface excrescences and/or pos-
itive cytologic washings whose tumors also ruptured
intraoperatively.
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the surgeon as fixed (P.012, 2). There was not a
significant difference in tumor mobility when com-
paring stages IA/B to stage ICr (P.094, 2), but there
was a higher rate of tumor fixation for ICs/w, with
rupture compared with ICs/w, no rupture (P.045,
2). Overall, the finding of a fixed mass did not affect
disease-free survival (HR 1.6, 95% CI 0.7–4.4; P.29)
(Table 2) or disease-specific survival (HR 1.2; 95% CI
0.4–4.2; P.77) (Table 3).
In univariable analyses, having positive cytologic
washings decreased disease-free survival (HR 5.2,
95% CI 2.1–12.3; P.001) and disease-specific sur-
vival (HR 5.9, 95% CI 1.8–19.3; P.005), whereas
having ovarian surface excrescences alone had no
effect on disease-free survival or disease-specific sur-
vival (Table 2 and 3). Controlling for intraoperative
capsule rupture, the presence of positive cytology
remained a predictor of worse disease-free survival
(HR 6.4, 95% CI 2.5–16.0; P.001).
Twenty-six patients were stage IC based on sur-
face involvement and/or positive cytologic washings
but had their tumors removed intact without rupture.
Fifteen (58%) had only positive cytology and no
evidence of surface involvement, eight (31%) had
surface involvement only and negative cytology, and
three (11%) had both positive cytology and surface
involvement. Twenty-three additional patients were
stage IC based on surface involvement and/or posi-
tive cytologic washings and also sustained capsule
rupture during surgery. Twelve (52%) had positive
cytology and tumor rupture; eight (35%) had surface
involvement and tumor rupture; and three (13%) had
both positive cytology and surface involvement in
addition to tumor rupture.
In univariable analysis, receiving platinum-based
chemotherapy was not associated with worse disease-
specific survival or disease-free survival (Table 2 and 3).
Overall, 106 of 161 (66%) patients received platinum-
based chemotherapy, and most (91 of 106) received
intravenous carboplatin and paclitaxel. Administration
of chemotherapy was stage-dependent, beingmost com-
mon for stage IC cases (74 of 87, 85%). Stage IC patients
were more likely to receive adjuvant treatment than
stage IA/B, because only 43% (32 of 74) of the stage
IA/B cases received platinum-based chemotherapy
(P.001, 2). Chemotherapy was administered in sub-
stages of IC as follows: Icr—34 of 38 cases (89%); ICs/w,
no rupture—18 of 26 cases (69%); ICs/w, with rup-
ture—22 of 23 cases (96%). There was a significant
difference in the percentage of patients receiving che-
motherapy among all substages.
Thirteen stage IC patients did not receive plati-
num-based chemotherapy. Reasons for not receiving
platinum-based chemotherapy among stage IC pa-
tients were as follows: stage Icr—one patient refused
and two patients did not receive chemotherapy for
reasons unknown; stage ICs/w, no rupture—one re-
ceived intraperitoneal P32, one had recurrent mela-
noma, one died on postoperative day 18 from a
myocardial infarction, and one did not receive che-
motherapy for reasons unknown; and stage ICs/w,
with rupture—1 received intraperitoneal P32. Intra-
peritoneal P32 was not considered equal to platinum-
based chemotherapy.22–24 An additional eight patients
received follow-up at outside institutions and receipt
of chemotherapy is unknown. Three were stage IA/B,
one was stage ICr, and four were stage ICs/w, no
rupture.
Despite adjuvant treatment, 4 (12%) of the 34 ICr
patients who received chemotherapy developed dis-
ease recurrence, and three died from their disease. In
addition, 17% (3 of 18) of stage ICs/w, no rupture
cases that received chemotherapy and 36% (8 of 22)
stage ICs/w, with rupture cases that received chemo-
therapy developed disease recurrence. Fifteen percent
(6 of 40) of stage ICs/w cases overall (those with capsule
rupture and those without) who received chemotherapy
died of their disease. Nine percent (3 of 34) of ICr cases
and only 3% (1 of 32) of IA/B cases who received
platinum-based chemotherapy died of disease.
Just over one half of the epithelial ovarian cancers
were FIGO grade 3 (Table 1). We dichotomized
tumors as either low-grade (FIGO grade 1 or 2) or
high-grade (FIGO grade 3) for analyses. In univari-
able analysis, higher grade demonstrated a tendency
to affect disease-free survival but did not reach statis-
tical significance (HR 2.3, 95% CI 1.0–5.9; P.064).
Higher grade did portend a worse disease-specific
survival (HR 5.5, 95% CI 1.4–36.1; P.011) (Table 2).
Fig. 2. Disease-free survival in stage IA/B and stage IC
secondary to capsule rupture only (ICr); (P.12, log-rank
test). ICr, stage IC, secondary to capsule rupture only.
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Additionally, there was a higher likelihood of receiving
platinum-based chemotherapy associated with high-
grade tumor (P.001, 2). The most common histology
was endometrioid (37%), followed by clear cell (22%),
serous (18%), mucinous (17%), and other (mixed, tran-
sitional cell, and seroanaplastic) histologies (6%). There
was no difference in disease-free survival or disease-
specific survival based on histologic subtype.
DISCUSSION
The effects of intraoperative capsular rupture on
outcomes in stage I epithelial ovarian cancer have
been difficult to elucidate due to the conflicting
published literature and the heterogenous populations
of patients included in these reports leading to flawed
conclusions. Most notably, prior publications have
included, or been comprised of, a large percentage of
incompletely staged patients,2,10,16,18,19,21 patients who
received non–platinum-based chemotherapy19 or ra-
diation as their adjuvant therapy,21 and the inclusion
of borderline tumors.16 The cohort of women that we
studied was highly homogeneous, because all of them
had invasive epithelial ovarian cancer, underwent
complete staging procedures, and if adjuvant therapy
was administered, it was a platinum-based regimen.
In this retrospective, two-institution study, we ana-
lyzed the importance of intraoperative tumor rupture on
prognosis in a uniform cohort of early stage epithelial
ovarian cancer. We observed both a shorter time to
disease recurrence and shorter disease-specific survival
associated with intraoperative capsule rupture both
alone and when controlling for positive cytology, which
was also an independent predictor of worse disease-free
survival and disease-specific survival. While positive
cytology was a significant predictor of worse prognosis,
washings were collected before tumor manipulation and
capsule rupture (if rupture occurred) suggesting that
malignant cells within the pelvis and abdomen are an
inherent finding at the time of surgery for some patients.
Capsule rupture, however, may be preventable with
careful surgical technique.
We noted a clinically significant difference in
disease-free survival and disease-specific survival be-
tween stage IA/B and stage ICr patients; however,
this difference did not reach statistical significance
(Figure 2). We attribute this to the small number of
recurrences and deaths from disease in both groups
and while analysis of a larger number of IA/B and ICr
patients is warranted, this factor should be considered
when planning adjuvant therapy. The worst disease-
free survival and disease-specific survival were ob-
served in patients who had tumor rupture in addition
to surface excrescences and/or malignant cells
present in their pelvic washings. Thus, it seems that
intraoperative capsule rupture further worsens the
prognosis of those women who are already stage IC
based on the unalterable findings of surface involve-
ment and/or positive cytology.
One of the strengths of our study is the restriction
to cases that were comprehensively staged, including
pelvic washings, hysterectomy, bilateral salpingo-oo-
phorectomy, omentectomy, pelvic and paraaortic
lymphadenectomy, and peritoneal biopsies. An addi-
tional strength of the study is that all patients treated
with intravenous chemotherapy received platinum-
based regimens. Despite our restrictions, our findings
are consistent with the most recent published data
which also suggests there is a worse prognosis for
stage I patients who have intraoperative capsule rup-
ture.18–21 A limitation in any retrospective surgical
series is the dependence upon operative notes for
intraoperative factors, such as the presence of peritu-
moral adhesions, which may also contribute to intra-
operative rupture. In addition, when comparing stage
IA/B cases to stage ICr cases, we lacked the power to
show a statistically significant difference in disease-
free survival and disease-specific survival despite the
HR of 2.7 and 5.3, respectively.
When considering why intraoperative capsular rup-
ture might be an important prognostic factor, we devel-
oped several hypothesis-driven questions. First, is tumor
fixation the true prognostic indicator and the capsule
rupturing during removal simply a surrogate of tumor
immobility? Although fixed tumors were more likely to
rupture, neither recurrence nor death from disease were
associated with mass immobility. Importantly, we also
noted that tumor immobility did not correlate with
surface involvement on final pathology. Second, are we
seeing a prognostic effect of lag time between diagnosis
(ie, laparoscopic salpingo-oophorectomy) and definitive
staging? In this study, no patients were included whose
tumors were removed for diagnosis and referred weeks
later for definitive surgical management. All of the
women in this study underwent immediate staging by a
gynecologic oncologist and irrigation of the peritoneal
cavity at the time of frozen-section diagnosis. This
eliminates lag time as a factor.
We are left suggesting two reasonable concepts
for why intraoperative rupture may affect outcomes.
First, that intraoperative spread of viable tumor oc-
curs at the time of rupture. This suggests very careful
avoidance of rupture is warranted, and if it occurs,
immediate and copious irrigation should be per-
formed, perhaps before completion of staging opera-
tion to avoid seeding retroperitoneal spaces and then
again at the end of surgery. A second reasonable
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explanation is that occult invasion by cancer of the
capsular surface exists, which predisposes to rupture
at that site intraoperatively. After rupture it may be
more difficult to histologically identify microscopic
surface involvement at the rupture site. And thus,
rupture is merely reflective of innately more aggres-
sive tumor biology. Gene expression studies compar-
ing unruptured compared with ruptured cases may
lend useful information on the basic biologic proper-
ties of these two clearly distinct types of cancers.
Overall, this study supports previous findings that
intraoperative capsule rupture leads to a worse disease
prognosis. This should be considered when counseling
patients and considering adjuvant therapy, particularly
when considering duration of treatment, because many
authors are now suggesting three cycles of adjuvant
chemotherapy may be sufficient for early stage dis-
ease.3,25 Our data suggest that current treatment regi-
mens leave patients at high risk of recurrence and death
within 5 years for stage I cases with surface involvement
and/or positive cytology and tumor rupture. This should
serve as reminder to both patient and oncologist of the
significance of this disease even in early stage cases.
Obviously, careful removal of an intact cystic mass,
even in the setting of adhesions, should be the goal in the
surgical management of stage I epithelial ovarian cancer.
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